Dr. Kuzel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15300 West Ave
Robert H Lurie Comp Ca Ctr
Orland Park, IL 60462Phone+1 708-226-2513Fax+1 312-942-3192
Summary
- I am the Samuel G Taylor III Professor of Oncology, and the Chief of the Division of Hematology/Oncology and Cell Therapy at Rush University since June 2016. Prior to that I spent 26 years as a Professor of Medicine and Dermatology in the Division of Hematology/Oncology at Northwestern University, Feinberg School of Medicine. I have focused my career on the design and execution of clinical trials with a specific focus on experimental therapeutics, especially phase I and phase II therapeutics rationally designed to exploit molecular and/or protein alterations within tumor cells and immunotherapeutic approaches/agents. Agents utilized have included chemotherapy drugs, targeted agents, cytokines, vaccines, and other novel immunotherapeutics. I have been a Co-PI on a SPORE in Prostate Cancer at Northwestern focused on immunomodulation to reverse resistance to oral novel anti-androgen therapies (the grant is in NCE thru Aug 2021). I have also had Prostate Cancer Foundation and NIH funding for translational agent development. I also worked in the area of shared decision making and identification of adverse events associated with drug therapy of cancer. I have served on a number of NCI site visit teams as a reviewer for Program Projects for 1) Immunotherapy in renal cell Ca, 2) Melanoma with dendritic cell-based immunotherapy approaches, and 3) Cellular immunotherapy, as well as 4) Community based NCI centers (NCOROP), and Novel Statistical Clinical Programs. In addition, I participated on several NCCN guidelines committees including Kidney/Testis and Bladder and Prostate at various times. I serve on multiple Data Monitoring Committees of phase II and III global check point inhibitor clinical trials.
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
- University of Michigan Medical SchoolClass of 1984
- University of MichiganBA, Biomedical Sciences, Cum Laude, 1978 - 1981
- University of MichiganB.S., Biomedical Sciences, 1981
Certifications & Licensure
- IL State Medical License 1984 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018, 2020
- America's Top Doctors Castle Connolly, 2008-2017
- America's Top Doctors for Cancer Castle Connolly, 2007-2017
- Join now to see all
Clinical Trials
- Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1991 Oct 01
- Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1999 May 20
- Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1998 May 01
- Join now to see all
Publications & Presentations
PubMed
- 122 citationsIntratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancerJenna H. Newman, C. Brent Chesson, Nora L. Herzog, Praveen K. Bommareddy, Salvatore M. Aspromonte
Proceedings of the National Academy of Sciences of the United States of America. 2020-01-14 - 361 citationsNCCN clinical practice guidelines in oncology: kidney cancer.Robert J. Motzer, Neeraj Agarwal, Clair J. Beard, Graeme B. Bolger, Barry Boston
Journal of the National Comprehensive Cancer Network. 2009-06-01 - 123 citationsPhase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell LymphomaDebra L. Breneman, Madeleine Duvic, Timothy M. Kuzel, Richard C. Yocum, Joseph Truglia
Archives of Dermatology. 2002-03-01
Journal Articles
- Type 2 Innate Lymphoid Cells Impede IL-33–Mediated Tumor SuppressionTimothy M Kuzel, Bin Zhang, The Journal of Immunology
- The Present and Future Cardiovascular Medicine and Society the Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (Or Onco-Cardiology) and Call to ActionAgne Paner, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Tochi M Okwuosa, Nicole Prabhu, Kim A Williams, ScienceDirect
- The efficacy of lenvatanib and everolimus in Chromophobe-type non-Clear Cell Renal Cell Cancer: A case report and Literature reviewSchwartz C, Pfanzelter N, Kuzel TM, Clin Genitourin Cancer, 1/25/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs LymphomaTimothy M. Kuzel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact of use of Phosphodiesterase Type 5 Inhibitors (PDE5-I) after Radical Prostatectomy (RP) on Biochemical Recurrence-free (BCRF) and Overall Survival (OS): A Retro...Arden B. Roston, Irene B. Helenowski, William Catalona, Robin Leikin, Michael Gurley, Luke Trapp, Borko Jovanovic, Timothy M. Kuzel, J Clin Oncol; Proc of GU ASCO, 1/1/2017
- Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell...Sumanta Pal, Robert J Motzer, Mayer Fishman, Raymond McDermott, Jose Passos Coelho, Evgeniy Kopyltsov, Xavier Garcia del Muro Solans, Jesús Garcia Donas, Ramazan Yildi..., J Clin Oncol; Proc of GU ASCO, 1/1/2017
- Join now to see all
Lectures
- Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...London, United Kingdom - 1/13/2017
- Immunotherapy of Cancer1/1/2012
- A phase 2 mutli-center, randomized, open-label study of two dose levels of IMO-2055 in Patients with metastatic or recurrent Renal Cell Carcinoma.1/1/2009
- Join now to see all
Other
- The use of Gemcitabine in metastatic urothelial transitional cell cancerKuzel TM and Stadler WM, Lilly Monograph
1/1/1996 - Book Review of --Atkins MB and Mier JW. Therapeutic Applications of Interleukin-2.Kuzel TM, Doody's Health Sciences Book Review Annual
1/1/1993 - Interferons: Basic Principles and Clinical Applications.Kuzel TM. Book Review of --Estrov Z, Kurzock R, and Talpaz M, Doody's Health Sciences Book Review Annual
1/1/1993
Press Mentions
- Combination Treatment Improves Survival in Advanced Prostate Cancer with Genetic MutationsSeptember 6th, 2024
- Rush Earns ASCO QOPI Certification for High-Quality Cancer CareSeptember 5th, 2019
- Personalized Vaccine Helps Patients Fight Ovarian CancerApril 12th, 2018
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: